Company intelligence / Profile preview

EvolveImmune Therapeutics

Branford, Connecticut, United Stateslinkedin.com ↗

Ownership: Private
Development stage: Preclinical

Overview

The company is developing novel T-cell engagers with integrated CD2 co-stimulation. Lead candidate EVOLVE104 has shown promising preclinical results for solid tumors with favorable pharmacokinetic and toxicity profiles. EVOLVE205 is being developed for hematologic tumors.

Therapeutic areas: Oncology
Modalities: Multifunctional biotherapeuticsT-cell engagersAntibody-based therapies
Industry: Biotech

Drug pipeline

7 assets

EVOLVE104

6 more assets in the full pipeline.

Request access →

Partnerships

AbbVieBristol Myers Squibb

Beyond the preview

Go deeper on EvolveImmune Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EvolveImmune Therapeutics.

Explore the full profile